… science and clinical practice of cancer immunotherapy. Nevertheless, as … cancer
immunotherapy to finally come of age. This transition coincides with another development of the …

Cancer immunotherapy comprises a variety of treatment approaches, incorporating the
tremendous specificity of the adaptive immune system (T cells and antibodies) as well as the …

It is 20 years since the demonstration that immune stimulation of metastatic tumors with
interleukin-2 (IL-2) could cause the regression of established human cancers. 1 IL-2 is a …

Lung carcinoma is the leading cause of death by cancer worldwide. When possible, surgery
is the best treatment strategy for patients with non–small-cell lung cancer. However, even …

… status of cancer immunotherapy in these three categories. … Hundreds of cancer immunotherapy
clinical trials have been … progress in three cancer immunotherapy categories, considered …

… As Nature Communications celebrates a 10-year anniversary, the field has witnessed the
transition of cancer immunotherapy from a pipe dream to an established powerful cancer …

Cancer immunotherapy—Science’s 2013 breakthrough of the year—took off in 2014. Almost
weekly, reports described patients on immunotherapies living longer than those taking …

For most patients with advanced or recurrent non-small-cell lung cancer (NSCLC),
chemotherapy is the mainstay of treatment, leading to modest improvements in progression-free …

… Two immune-checkpoint receptors are currently the focus of cancer immunotherapy,
cytotoxic T lymphocyte-associated antigen 4 (CTLA4) and programmed cell death protein 1 (PD1). …

Compared with the earlier incidence of acute infectious diseases, the introduction of
vaccines has been one of the major public health success achievements. In contrast, vaccine …